Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.

Schilling, William H K; Mukaka, Mavuto; Callery, James J; Llewelyn, Martin J; Cruz, Cintia V; Dhorda, Mehul; Ngernseng, Thatsanun; Waithira, Naomi; Ekkapongpisit, Maneerat; Watson, James A; Chandna, Arjun; Nelwan, Erni J; Hamers, Raph L; Etyang, Anthony; Beg, Mohammad Asim; Sow, Samba; Yavo, William; Allabi, Aurel Constant; Basnyat, Buddha; Sharma, Sanjib Kumar; Amofa-Sekyi, Modupe; Yonga, Paul; Adler, Amanda; Yuentrakul, Prayoon; Cope, Tanya; Thaipadungpanit, Janjira; Rienpradub, Panuvit; Imwong, Mallika; Abdad, Mohammad Yazid; Blacksell, Stuart D; Tarning, Joel; Goudjo, Frejus Faustin; Dossou, Ange D; Konaté-Touré, Abibatou; Assi, Serge-Brice; Ouffoué, Kra; Nasronudin, Nasronudin; Rachman, Brian Eka; Romadhon, Pradana Zaky; Dewanto, Didi Darmahadi; Heryana, Made Oka; Novi, Theresia; Pasaribu, Ayodhia Pitaloka; Mutiara, Mutiara; Nasution, Miranda Putri Rahayu; Khairunnisa, Khairunnisa; Dalimunthe, Fauzan Azima; Airlangga, Eka; Fahrezzy, Akmal; Subronto, Yanri; Ananda, Nur Rahmi; Rahardjani, Mutia; Rimainar, Atika; Lucinde, Ruth Khadembu; Timbwa, Molline; Onyango, Otieno Edwin; Agutu, Clara; Akech, Samuel; Hamaluba, Mainga; Kipyego, Jairus; Ngachi, Obadiah; Haidara, Fadima Cheick; Traoré, Oumar Y; Diarra, François; Khanal, Basudha; Dahal, Piyush; Shrestha, Suchita; Rijal, Samita; Kabore, Youssouf; Adehossi, Eric; Guindo, Ousmane; Qamar, Farah Naz; Kazi, Abdul Momin; Woodrow, Charles J; Laird, Steven; Cheeba, Maina; Ayles, Helen; Cheah, Phaik Yeong; Taylor, Walter R J; Batty, Elizabeth M; Chotivanich, Kesinee; Pukrittayakamee, Sasithon; Phumratanaprapin, Weerapong; von Seidlein, Lorenz; Dondorp, Arjen; Day, Nicholas P J; White, Nicholas J; Laird, Steven

Author

Schilling, William H K
Mukaka, Mavuto
Callery, James J
Llewelyn, Martin J
Cruz, Cintia V
Dhorda, Mehul
Ngernseng, Thatsanun
Waithira, Naomi
Ekkapongpisit, Maneerat
Watson, James A

Show all

Affiliation

William H. K. Schilling ,Mavuto Mukaka,James J. Callery,Martin J. Llewelyn,Cintia V. Cruz,Mehul Dhorda,Thatsanun Ngernseng,Naomi Waithira,Maneerat Ekkapongpisit,James A. Watson,Arjun Chandna,Erni J. Nelwan,Raph L. Hamers, [ ... ],on behalf of the COPCOV Collaborative Group

Publication date

2024-09-12

Metadata

Show full item record

Abstract

No Abstract

Citation

12 September 2024, Bangkok – Four years after being derailed by scientific fraud and politicised science in the first year of the pandemic, COPCOV, the world’s largest COVID-19 chemoprevention study, finally published results today that showed that hydroxychloroquine (HCQ) does have a moderate benefit in preventing COVID-19. Published in PLOS Medicine, COPCOV found a 15% reduction in symptomatic COVID-19 in those taking the medication vs those taking a placebo. The study also showed a significant reduction in all-cause respiratory illness, as well as fewer days lost to work because of illness. Importantly, hydroxychloroquine was well tolerated and safe.

Type

Article
Other